欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > Apoptosis > TH-302

浏览历史

S81103

TH-302

源叶(MedMol) 99%
  • 英文名:
  • TH-302
  • 别名:
  • (1-methyl-2-nitro-1H-imidazol-5-yl)methyl N,N-bis(2-bromoethyl)phosphordiamidate
  • CAS号:
  • 918633-87-1
  • 分子式:
  • C9H16Br2N5O4P
  • 分子量:
  • 449.04
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S81103-1mg 99% ¥300.00元 5 - - - EA 加入购物车
源叶(MedMol) S81103-2mg 99% ¥500.00元 8 - - - EA 加入购物车
源叶(MedMol) S81103-5mg 99% ¥750.00元 9 - - - EA 加入购物车
源叶(MedMol) S81103-10mg 99% ¥1150.00元 8 - - - EA 加入购物车
源叶(MedMol) S81103-25mg 99% ¥2400.00元 8 - - - EA 加入购物车
源叶(MedMol) S81103-50mg 99% ¥3700.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S81103-100mg 99% ¥6500.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: Evofosfamide (TH-302) is a hypoxia-activated prodrug with IC50 of 10 μM and 1000 μM in hypoxia (N2) and normoxia (21% O2), respectively.
  • 靶点: Hypoxia-activated prodrug;Apoptosis; Others
  • 体内研究:
    Evofosfamide (TH-302) is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. The mean values of normalized Ktrans decrease 69.2% for Evofosfamide (TH-302)-treated mice in Hs766t tumors, decrease 46.1% for Mia PaCa-2 tumors and increase 4.9% in SU.86.86 tumors. Both changes for Hs766t and Mia PaCa-2 treatment groups are statistically significant (P<0.01) when compare to their own control group. A significant reduction in the hypoxic fraction (HF) to 2.1%±4.7% is seen after 95% oxygen breathing (P<0.001), whereas 7% oxygen breathing significantly increase the HF to 29.5%±14.7% (P=0.029). Exposing rhabdomyosarcoma-bearing rats to increasing oxygen conditions abolish the effect of TH-302 and reduce the T4×SV from 20.4±3.5 to 15.3±2.5 days (P=0.007), whereas control animals have an increased T4×SV. Upon combination with radiotherapy, the T4×SV of TH-302-treated tumors decrease from 30.8±5.9 (Evofosfamide (TH-302)+radiotherapy) to 25.7±2.9 days (Evofosfamide (TH-302)+radiotherapy+95% O2).
  • 参考文献:
    1. Meng F, et al. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21;15:422. 2. Zhang X, et al. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016 May 26;11(5):e0155289. 3. Peeters SG, et al. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 1;21(13):2984-92.
  • 溶解性: DMSO  :  94  mg/mL  (209.34  mM;  Need  ultrasonic  and  warming)    H2O  :  4.35  mg/mL  (9.69  mM;  ultrasonic  and  warming  and  heat  to  60°C)
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.227 ml 11.135 ml 22.27 ml
    5 mM 0.445 ml 2.227 ml 4.454 ml
    10 mM 0.223 ml 1.113 ml 2.227 ml
    50 mM 0.045 ml 0.223 ml 0.445 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。